Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

SPP2 neuro/psych > seizure disorder > Flashcards

seizure disorder Flashcards

You may prefer our related Brainscape-certified flashcards:
Psychology 101 flashcards GRE® Psychology flashcards
1
Q

siezure

A

paroxysmal (sudden) disorder of the CNS characterized by abnormal cerebral neuronal discharges with or without loss of consciousness
some synchrony to them
result of disordered, synchronous, excessivem and rhythmic firing of a population of brain neurons

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

convulsion

A

specific seizure type where the attack is manifested by involuntary muscle contractions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

epilepsy

A

repeated seizures due to damage, irritation and/or chemical imbalance in the brain which leads to a sudden, excessive, synchronous electrical discharge

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

seizure originates in the ___

A

gray matter of ant cortical or subcortical area of the brain (thalamus)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

focal or partial seizures

A 
60%
activity starts in 1 area of the brain
only part of the brain is affected
usually due to a lesion
can evolve to generalized seizure
simple VS complex
simple- no loss of consciousness or altered awareness, sensory disturbances
complex - altered awareness
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

generalized seizures

A

40%
no focal point
both hemispheres involved
typically involve a loss of consciousness
referred to as “primary” or “idiopathic”
most presumed to be genetic
absence, tonic clonic, myoclonic, clonic, tonic, atonic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

simple partial seizure pathophysiology

A

25% of partial seizures
limited convulsions (jerking limited to 1 body part)
limited sensory disturbance
NO loss of consciousness
subjective experiences (auras): abdominal discomfort, sense of fear, altered taste, unpleasant smell, result of abnormal electrical activity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

complex partial seizure pathophysiology

A

75% of partial seizures
clouding of consciousness, altered awareness
staring
automatisms (repetitive motor behaviors): clicking, chewing, lip smacking with no memory
disturbances of visceral, emotional and autonomic systems
followed by confusion, fatigue and throbbing headache (postictal state)
aura is common*

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

postictal state

A

after seizure (complex), pt will not recover a normal level of consciousness immediately
may last seconds to hours depending on: area of brain affected, length of seizure, use of AEDs, age
Sxs: confusion, disorientation, anterograde amnesia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

absence seizures pathophysigology

A

generalized seizure
typical or atypical
typical (petit-mal): *brief loss of consciousness, staring or eye flickering, begin abruptly, repetitive, *no convulsions, aura, or postictal period
(no consciousness, no convulsions)
atypical: slower onset, more difficult to control pharmacologically than typical

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

non-absence generalized seizures

A

myoclonic: shock-like contraction of the muscles, isolated jerking of head, trunk, body
tonic: children, rigidit as a result of increased tone in extensor muscles
clonic: babies and young children, rapid, repetitive motor activity
atonic: loss of muscle tone, fall of standing (drop attacks)
tonic-clonic: tonic immediately followed by clonic phase, “grand-mal”, characteristic of epilepsy
status epilepticus: single prolonged seizure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

tonic-clonic seizure pathophysiology

A

generalized, “grand mal”
most dramatic of all epileptic seizures
first phase: tonic; begins abruptly often with diaphragm contraction, rigidity in all extremities (15-30 seconds), tonus is interrupted by a tremor that corresponds to relaxation
second phase: clonic; begins as relaxation becomes more prolonged, involves violent jerking (hyperpolarization and depolarization back and forth) that lasts 1-2 minutes
jerking followed by stuperous state
tongue or cheek may be bitten
urinary incontinence is common
primary have no evidence of localized onset
secondary start as partial seizure, could be an aura

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

status epilepticus pathophysiology

A

repetitive seizure activity in which the patient does not regain consciousness between seizures OR a continuous, single seizure episode lasting over 30 minutes
aka: greater than 5 minutes of continuous seizure activity OR recurrent seizure activity without return to baseline
therapeutic goal is to bring seizures under control within 60 minutes to minimize neurologic and CV complications, including: abnormal glucose utilization, compromised CNS blood flow (O2), lactic acid accumulation, CV collapse (arrhythmia), long term impact on cognitive function and worsening of seizure disorder

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

excitatory NTs

A

AMPA, NMDA, Ca

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

inhibitory NTs

A

GABA, K

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

epilepsy statistics

A

1-2% of population, 1/5 will experience some seizure activity in their lifetime, 50-75% of pts w epilepsy are successfully treated with therapeutic agents
**drug therapy can be gradually withdrawn in pts who have been clinically-free of seizures for 2-5 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

triggers of SE

A

underlying conditions: prenatal injury, cerebrovascular Dx, brain tumors, head trauma, infection, hemorrhage, anoxia
general perturbations: metabolic disturbances (hyperventiliation, blood gas, pH, hypoglycemia), sleep deprivation, stress, alcohol withdrawl, *AED withdrawl (sudden discontinuation), repetitive light stimulation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

drugs that aggravate or inc risk of seizure

A

alcohol, theophylline, CNS stimulants, bupropion, OCs, withdrawl from depressants, clozapine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

4 MOAs of anticonvulsant drugs

A
  1. inhibition Na influx, prolong inactivation of Na channels
  2. inhibition of Ca influx (critical for absence seizures)
  3. stimulation of GABA-mediated neuronal inhibition
  4. inhibition of excitatory transmitters (glutamate)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

phenytoin

A

***Strong P450 and UGT inducer; teratogen – pregnancy category D, therapeutic serum conc 10 – 20 mcg/mL (calculate free phenytoin with albumin); boxed warning – cardiovascular events; decreased bone mineral density, SJS/TEN, nystagmus, ataxia, double vision, hepatotoxicy, hirsutism, gingival hyperplasia, alteration of Vitamin D metabolism; osteoporosis; status epilepticus – fosphenytoin dosed in phenytoin equivalents preferred to reduce risk of arrhythmias, hypotension, purple glove syndrome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

carbamazepine

A

**Partial/generalized seizures, P450 inducer (including auto‐inducing own metabolism), hyponatremia, aplastic anemia, SJS/TEN (HLA‐B1502 testing in patients of Asian descent), DRESS syndrome (HLA‐ A*3101 testing – Northern European descent (not required, suggested), therapeutic range *4 – 12 mcg/ml, electrolytes, CBC w/platelets, decreased efficacy of OCs, teratogen – category D (some generics available)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

drugs that inhibit Na presynaptic Na channels

A

phenytoin, carbamazepine, lacosamide, lamotrigine, valproate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

barbituates

A

used to treat partial seizures and generalized tonic-clonic
phenobarbital: drug of choice in infants up to 2 months of age (sedative)
MOA: binds to an allosteric regulatory site on the GABAa receptor, increases duration* of Cl- channel-opening events (and thus enhances GABA inhibitory signaling)
DI: induces liver cytochrome P450 enzymes
toxicity: sedation, physical dependence

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

benzodiazepines

A

used to treat partial seizures and generalized tonic-clonic
diazepam: especially useful for tonic-clonic status epilepticus; often administered as a rectal gel for acute control of seizure activity
MOA: binds to an allosteric regulatory site on the GABAa receptor, increases frequency* of Cl- channel-opening events (and thus enhances GABA inhibitory signaling
toxicity: sedation, physical dependence (tolreance), not for chronic treatment

clonazepam: useful for acute Tx of epilepsy and absence seizures*

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

drugs that inhibit post-synaptic GABAa receptors

A

phenobarbital, benzodiazepines

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

gabapentin MOA

A

increases GABA release

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

NMDA and AMPA receptors

A

used to treat partial seizures and generalized tonic-clonic
NMDA: glutamate binding triggers an influx of Na and *Ca and and efflux of K
AMPA: glutatamte binding triggers an influx of Na and and efflux of K

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

succinimides

A

used to treat absence seizures
MOA: blocks T-type Ca channels in thalamic neurons, T=type Ca channels are thought to be involved in generating the rhythmic cortical discharge of an absence attack
toxicity: GI distress, sedation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

drugs that inhibit Ca channels in the presynaptic neuron

A

ethosuximide, lamotrigine, levetiracetam, valproate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

levetiracetam MOA

A

MOA: binds the synaptic vesicular protein SV2A and thus interferes with synaptic vesicle release and neurotransmission, also appears to interfere with Ca entry through Ca channels and with intraneuronal calcium singaling

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

drugs that inhibit NMDA receptors

A

felbamate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

drugs that inhibit AMPA receptors

A

topiramate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

drugs that inhibit GABA transporter

A

tiagabine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

drugs that inhibit GABA transaminase

A

vigabatrim

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

always counsel on the interaction between anticonvulsants and ___

A

oral contraceptives

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

common co-morbidity to seizures

A

depression

37
Q

most common treatment of SE

A

IV benzodiazepines i.e. lorazepam

levetiracetam
valproate
lacosamide
phenobarbital
topiramate (PO only)
38
Q

successful anticonvulsant withdrawl my occur after a seizure free period of ___

A

2-5 years

39
Q

urgent control of SE

A

used after emergent initial for rapid attainment therapeutic serum conc of AED
IV fosphenytoin/phenytoin, valproate, levetiracetam
cont. infusion midazolam
consider re-initiation of prior effective anti-epileptic drug (why did status occur?)

40
Q

refractory SE

A

*identified by continuous EEG, not serum conc
use EEG to guide therapy
bolus intermittent treatment - doses of AED given every few hours based on individualized dose
IV dosing - valproate, levetiracetam, phenytoin/fosphenytoin, lacosamide
cont. infusion - usually given if history of refractory SE or breakthrough seizures when using blous intermittent
IV dosing - midazolam, propofol, pentobarbital

41
Q

phenytoin/fosphenytoin loading dose

A

phenytoin (hypotension limits infusion rate): 20 mg/kg IV, up to 50 mg/minute IV infusion

*fosphenytoin: 20 mg PE/kg IV, up to 150 mg PE/minute IV infusion

42
Q

oral phenytoin dosing considerations

A

use if calculating a new oral dose based on obtained serum conc after loading doses and seizure control
**must obtain phenytoin serum conc and serum albumin in the same blood draw
adjusted conc = observed/((0.25 x albumin) + 0.1)
therapeutic range: 10-20 mcg/ml

43
Q

valproate loading dose

A 
IV: 15-30 mg/kg
IV to PO conversion is 1mg:1mg
loading calc: Vd x (desired conc) x kg
Vd = 0.2
usual desired conc = 80 mcg/mL
44
Q

lamotrigine in seizures

A

**Broad spectrum anticonvulsant – 1st line agent, SJS/TEN* – dose titration required to minimize risk; may decrease efficacy of OCs at higher doses of lamotrigine; blurred vision, drowsiness, dizziness, decreased coordination (generic available – IR dosage form)

45
Q

Levetiracetam in seizures

A

**Broad spectrum anticonvulsant; IV dosing available for status epilepticus; 1st line agent; renal dosing for CrCl under 50 mL/min; ESRD – 500 – 1000 mg q24hr max, supplement 250 – 500 mg after dialysis; adults with partial seizures – ataxia, abnormal gait; adolescents (most commonly) – psychosis, worsening depression, unusual mood changes (generic available)

46
Q

valproate in seizures

A

***Broad spectrum; use not recommended in pregnancy – neural tube defects/lower IQ in offspring; serum concentration range – 50 – 125 mcg/mL; status epilepticus dosing available, including loading dose; may cause *hyperammonemia, thrombocytopenia, weight gain, nausea, vomiting, sedation, alopecia, polycystic ovarian syndrome (PCOS) – monitor CBC w differential/platelets, *LFTs, serum concentration; watch dispensing – IR capsules, DR tablets, ER tablets, sprinkle capsules (some are generic)

47
Q

zonisamide in seizures

A

***Contraindicated in sulfa allergy; partial/generalized tonic clonic; metabolic acidosis, renal calculi, ? DRESS syndrome?, drowsiness, tremor, weight loss

48
Q

Clobazam in seizures

A

partial and generalized tonic-clonic
**C‐IV controlled substance; 3A4 substrate, weak 3A4 inducer – possible decreased efficacy of OCs; 1, 5 – benzodiazepine (theoretically less abuse potential); significant withdrawal symptoms if stopped abruptly; indicated only as adjunct for Lennox‐Gastaut syndrome

49
Q

clonazepam in seizures

A

partial and generalized tonic-clonic
**C‐IV controlled substance; 3A4 substrate; pregnancy category D, indicated for myoclonic seizures; side effects – anterograde amnesia, paradoxical disinhibited behavior, significant withdrawal symptoms if stopped abruptly, respiratory depression, CNS depression; contraindicated in severe hepatic
dysfunction; generic available

50
Q

eslicarbazepine in seizures

A

partial and generalized tonic-clonic

  • Active metabolite of oxcarbazepine; prodrug metabolized to active form; 2C19 inhibitor; SJS/TEN (HLA‐B1502 testing in patients of Asian descent (required) and HLA‐A*3101 testing of patients of Northern European descent (not required), hyponatremia, blood dyscrasias (not as severe as carbamazepine)
    monitor: electrolytes
51
Q

ezobagine in seizures

A

**C‐IV controlled substance; CrCl under 50 mL/min = 600 mg max daily dose; boxed warning retinal abnormalities progressing to vision loss – eye exam baseline & every 6 months; QTc prolongation; urinary retention; gray/blue skin – sign of toxicity; memory impairment, hallucinations; UGT major substrate; partial/generalized tonic clonic

52
Q

felbamate in seizures

A

**Boxed warnings – aplastic anemia, hepatic failure – LFTs baseline and frequently thereafter (at least every 3 months), warn patients about signs of hepatic dysfunction, CBC w differential/platelets baseline and every 3 months – d/c if signs of bone marrow suppression; most commonly used for Lennox‐Gastaut syndrome (generic available)

53
Q

gabapentin in seizures

A

**Abuse potential although not a controlled substance; 100% renal clearance; CrCl 30 – 60 mL/min – max dose 1800 mg/day; not recommended CrCl under 30 mL/min; monitor renal function; sedation, peripheral edema; first‐line agent partial/generalized tonic clonic; also used for neuropathic pain (generic available)

54
Q

LACOSAMIDE in seizures

A

C‐V controlled substance; partial/generalized tonic clonic; IV dosing available for status epilepticus; 2C19 substrate and inhibitor; caution in cardiac conduction abnormalities – prolongs PR interval – visual disturbances; dizziness, ataxia, somnolence, double vision; idiosyncratic – hepatic impairment, 1st degree heart block

55
Q

oxcarbazepine in siezures

A

**3A4 substrate/inducer; 2C19 inhibitor; SJS/TEN (HLA‐B1502 testing in patients of Asian descent (required)), DRESS syndrome (HLA‐A*3101 testing in patients of Northern European descent – not required), hyponatremia (more common than with carbamazepine), blood dyscrasias (less common than with carbamazepine, NOT aplastic anemia); CBC w/differential/platelets, electrolytes (generic)

56
Q

Perampanel in seizures

A

***C‐III controlled substance; 3A4 major substrate, dosing adjustments if given with 3A4 inducers; boxed warning for serious/life‐threatening neuropsychiatric events; use with caution in patients with psychosis; gait disturbance, somnolence

57
Q

Phenobarbital in seizures

A

***C‐IV controlled substance; not commonly used in oral dosing in adults for seizure maintenance, may see in children; status epilepticus dosing for refractory status; pregnancy category D; 2C9 substrate; P450 and UGT strong inducer; LONG half‐life; somnolence, cognitive impairment; impaired calcium absorption; can be fatal in overdose (generic available)

58
Q

pregabalin in seizures

A

**C‐V controlled substance; partial/generalized tonic clonic; 100% renal elimination – dose adjustments in CrCl under 60 mL/min; angioedema, PR interval prolongation; dizziness, sedation, peripheral edema; monitor renal function; more commonly used for neuropathic pain and generalized anxiety disorder

59
Q

primidone in seizures

A

***Metabolized to phenobarbital; Pregnancy category D; strong P450 and UGT inducer; more commonly used to treat essential tremor; monitor LFTs and CBC with differential/platelets (generic)

60
Q

rufinamide in seizures

A

***Lennox‐Gastaut or refractory seizures; contraindicated in familial short QT syndrome; DRESS; SJS/TEN; somnolence, fatigue, ataxia, nausea

61
Q

tiagabine in seizures

A

***3A4 substrate – dose adjustments required for use with strong 3A4 inducers or inhibitors; may cause cognitive impairment; somnolence, tremor; use with caution off‐label for patient without seizure disorder (ie, as a mood stabilizer for bipolar disorder) and with hepatic dysfunction – may trigger seizures

62
Q

topiramate in seizures

A

“dopamax”

***3A4 substrate/inducer – may decrease efficacy of OCs, pregnancy category D, status epilepticus dosing – but is only PO dosing; warnings/precautions – nephrolithiasis, CNS depression, metabolic acidosis, oligohydrosis/hyperthermia; secondary angle‐closure gluacome; visual field defects; *cognitive impairment,, hyperchloremic non‐anion gap metabolic acidosis; monitor urinalysis, basic metabolic profile (for bicarbonate) every 6 months; dose titrate slowly (generic)

63
Q

vigabatrin in seizures

A

***35% renally cleared, otherwise UGT metabolism; renal dosing for CrCl under 80 mL/min; contraindicated in patients with other risk factors for irreversible vision loss (boxed warning), warnings for peripheral neuropathy, edema, anemia, neurotoxicity; side effects – depression, insomnia, weight gain, permanent loss of peripheral vision

64
Q

ethosuximide in seizures

A

**Indicated only for absence seizures; avoid in renal/hepatic dysfunction; 3A4 substrate; CBC
w/differential/platelets, basic metabolic profile – leukopenia, eosinophilia, psychiatric/sleep
disturbances, aggression; systemic lupus erythematosus, SJS/TEN (generic available)

65
Q

partial onset* seizures first line treatments

A

carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, valproate, lacosemide

66
Q

tonic-clonic* seizures first line treatments

A

carbamazepine, lamotrigine, oxcarbazepine, valproate

67
Q

absence* seizures first line treatments

A

ethosuximide, lamotrigine, valproate

68
Q

myoclonic* seizures first line treatments

A

levetiracetam, topiramate, valproate

69
Q

lennox-gastaut* syndrome seizures first line treatments

A

valproate, lamotrigine

70
Q

1A2, 2C9, 2C19 inducers

A

carbamazepine, phenobarbital, phenytoin, primidone

71
Q

3A4 inducers*

A 
CHILD SUPPORT
carbamazepine
clobazam
eslicarbamazepine
felbamate
lamotrigine
oxcarbazepine
phenobarbital
phenytoin
primidone
rufinamide
topiramate
first line agents that *DO NOT interact: levetiracetam, valproate, ethosuximide
others that do not interact: Zonisamide, Clonazepam, Ezobagine, Gabapentin, Lacosamide, Perampenel, Pregabalin, Tiagabine, Vigabatrin
72
Q

contraceptives and AEDs

A

can use progestin only contraceptives - depo provera

higher dose estrogen contraceptives

73
Q

SJS/TEN and pharmacogenomics

A

associated with carbamazepine, oxcarbazepine, eslicarbazepine
**pts of asain descent are more likely if they carry the HLA-B1502 allele
recommend to test for it before initiating treatment
therapy w these drugs is *CI in any patient who tests positive

74
Q

DRESS syndrome

A

drug reaction with eosinophilia and systemic symptoms or drug induced hypersensitivity syndrome
potentially life-threatening
dermatologic rxn
systemic multi-organ involvement
**associated with carbamazepine, lamotrigine, phenobarbital, phenytoin, valproate, zonisamide
HLA-A*3101 (usually asian or northern european)

75
Q

anticonvulsants and pregnancy

A

serum conc may change due to changes in Vd
category D - carbamazepine, clonazepam, fosphenytoin, phenobarbital, phenytoin, primidone, topiramate
**valproate is D or X - neural tube defects and decreased IQ (D for seizures)

76
Q

CV AE with AEDs

A 
QTc prolongationg: ezogabine
QTc shortening: rufinamide
PR interval changes: lacosamide, pregabalin (peripheral edema, caution in HF)
heart block: lacosamide
arrythmia: pheytoin/fosphenytoin
77
Q

natural seizure remedies

A

ketogenic diet

3:1 or 4:1 fats:carbs/proteins

78
Q

non-drug seizure interventions

A

vagus nerve stimulation: coil around vagus nerve, helps reduce depression
deep brain stimulation
responsive neurostimulation
surgery - separate hemispheres

79
Q

lorazepam

A

**Not commonly used as an oral dose for maintenance control of seizures (abuse potential); common 1st line agent for status epilepticus; significant withdrawal symptoms if taken orally for maintenance treatment and abruptly stopped; CAN be used in hepatic dysfunction

80
Q

risk factors for recurrence

A 
under 2 years seizure free
*Onset of seizure after age 12
2-6 years before good seizure control in treatment
*Partial seizures (most common)
*Abnormal EEG throughout treatment
81
Q

lamotrigine dosing*

A 
UGT substrate with risk of SJS, with other drugs effecting UGT, must be dosed differently
none: 
25 mg QD x 14
50 mg QD x 14
100 mg QD x 7
200 mg QD
concomitant inducer (carbamazepine, phenytoin):
50 mg QD x 14
100 mg QD x 14
200 mg QD x 7
400 mg QD
concomitant inhibitor (valproate):
25 mg QOD x 14
25 mg QD x 14
50 mg QD x 7
100 mg QD
82
Q

anticonvulsant withdrawal syndromes

A

Associated with abrupt discontinuation of anticonvulsant drug therapy
May cause recurrence of seizures, so doses of anticonvulsants should always be tapered for discontinuation
Worst offenders: clobazam, clonazepam, ezogabine, perampanel, Phenobarbital, pregabalin, gabapentin
Tapers can be over 6 months, if seizures recur, put back on the last dose of the taper regimen

83
Q

depression in epilepsy

A

Patients with epilepsy have a high-risk of co-morbid depression
Antidepressants also have P450 isoenzyme metabolism, requires careful evaluation of anticonvulsant therapy and use of appropriate antidepressants
**Use of bupropion should be avoided in patients with uncontrolled seizure disorders, as it can increase the risk of seizures and seizure frequency, May be can be tried if seizures are controlled and it’s the best therapy, but should be monitored carefully

84
Q

cardio vascular adverse events

A 
QTc prolongation: ezobagine
QTc shortening: rufinamide
PR interval changes: lacosamide, pregabalin
Heart block: lacosamide
Arrhythmia: phenytoin, fosphenytoin
85
Q

electrolyte abnormalities/metabolic acidosis/mineral metabolism

A

SIADH (hyponatremia): carbamazepine, eslicarbazepine, oxcarbazepine
Metabolic acidosis, renal calculi: zonisamide
**Altered Vit D metabolism and decreased calcium concentrations leading to osteoporosis with long-term use: phenytoin
Decreased serum bicarbonate leading to metabolic acidosis, nephrolithiasis: topiramate

86
Q

Psychiatric Side Effects of Anticonvulsants

A

Levetiracetam: behavior abnormalities, including psychosis, suicidal thoughts/behaviors, unusual mood changes, worsening of depression
Perampanel: boxed warning for dose-related serious and/or life-threatening neuropsychiatric events
Valproate: acute mental status changes
Tiagabine: risk of seizures if used off-label
Topiramate: cognitive dysfunction if dose is increased too rapidly

87
Q

Visual Abnormalities

A

Phenytoin: associated with nystagmus
Ezobagine: retinal abnormalities that may lead to visual loss
Topiramate: labeling for vision loss, monitor closely
**Vigabatrin: contraindicated in patients who have other risk of factors for irreversible vision loss; vision assessments should be performed prior to initiation of therapy and every 3-6 months

88
Q

drug related information**

A

Ezobagine: warning of urinary retention, grey-blue/brown skin discoloration (sign of toxicity), QTc prolongation
Phenytoin: risk of osteoporosis
Topiramate: Adverse effect of cognitive dysfunction
Vigabatrin: contraindicated in patients with other risk factors for irreversible vision loss

SPP2 neuro/psych (5 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions